Carisma Therapeutics (CARM) Expected to Announce Earnings on Monday

Carisma Therapeutics (NASDAQ:CARM) is anticipated to release its earnings data before the market opens on Monday, March 31st. Analysts expect Carisma Therapeutics to post earnings of ($0.17) per share and revenue of $5.42 million for the quarter.

Carisma Therapeutics Stock Down 7.1 %

Shares of NASDAQ:CARM opened at $0.36 on Friday. The firm has a market capitalization of $14.94 million, a PE ratio of -0.23 and a beta of 1.55. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. Carisma Therapeutics has a 52-week low of $0.35 and a 52-week high of $2.36. The firm has a fifty day moving average of $0.44 and a 200 day moving average of $0.68.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CARM. BTIG Research cut Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Robert W. Baird cut shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $10.00 to $1.00 in a research report on Thursday, December 12th. HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. Evercore ISI reaffirmed an “in-line” rating and issued a $0.70 price objective (down previously from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday, December 11th. Finally, Baird R W cut shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Five equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $4.94.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.